J.P. Morgan Maintains Rating, PT Following Presentation By ARIA

Loading...
Loading...
J.P. Morgan is maintaining its Overweight rating, along with its $10 price target on Ariad Pharmaceuticals
ARIA
following the company's recent presentation at the ASCO Conference. Says J.P. Morgan, in its report, “We reiterate our OW rating on ARIA following presentations yesterday afternoon (after market close) of the Ph3 SUCCEED results for rida in soft tissue and bone sarcoma at the annual American Society of Clinical Oncology (ASCO) conf. in Chicago. Overall, we believe the data are compelling enough to warrant approval. While we continue to view ponatinib (
CML
) as the key value driver (pivotal data expected 4Q), we suspect increasing confidence in rida could add further support to the stock.” ARIA closed at $7.91 yesterday.
Posted In: Analyst ColorAnalyst RatingsARIAD Pharmaceuticals Inc.BiotechnologyComputer Storage & PeripheralsHealth CareInformation TechnologyJ.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...